{"product_id":"henlius-business-model-canvas","title":"Shanghai Henlius Biotech Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHenlius Business Model Canvas: A Clear Blueprint for Biosimilars and Innovative Biologics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the strategic framework behind Shanghai Henlius Biotech's business model-this concise Business Model Canvas highlights how the company delivers clinical and commercial value, aligns partnerships and capabilities, and monetizes biosimilars and innovative biologics across oncology, autoimmune, and ophthalmic care; ideal for investors, strategists, and founders seeking a practical way to understand the company's value proposition, customer focus, and growth logic.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Synergy with Fosun Pharma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a core subsidiary of Fosun Pharma (Shanghai Fosun Pharmaceutical Group Co., Ltd.), Henlius gains integrated financial backing-Fosun Pharma reported RMB 76.6 billion revenue in 2024-plus access to its nationwide sales network covering 2,500+ hospitals, boosting Henlius' market reach and reimbursement penetration. This tie gives Henlius steady capital for capital-intensive R\u0026amp;D (R\u0026amp;D spend in Fosun Pharma 2024: RMB 4.8 billion) and credibility in China's healthcare sector, supporting long-term growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHenlius partners with international pharma leaders-Organon, Sandoz, and Accord Healthcare-granting direct commercial channels into the US, EU, and 50+ emerging markets; these alliances helped drive Henlius' 2024 international biosimilar revenue to about US$120m (company filings, 2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHenlius partners with top universities and institutes-including Fudan University and Shanghai Institute of Materia Medica-to co-develop early-stage oncology and immunology leads, sharing lab resources and IP where 2024 R\u0026amp;D spend hit RMB 1.02 billion (up 18% YoY). These ties give Henlius faster access to novel biologics and CRISPR\/ADC platforms, keeping its pipeline aligned with academic trends and reducing preclinical timeline by an estimated 12 months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHenlius contracts specialized clinical research organizations (CROs) to run multi-regional trials across Asia, Europe, and North America, ensuring data meets NMPA, EMA, and FDA standards and supporting 40+ ongoing global studies as of end-2025.\u003c\/p\u003e\n\u003cp\u003eThe outsourcing model cuts fixed costs, letting Henlius advance a 30-drug pipeline while keeping R\u0026amp;D headcount lean and trimming per-trial overheads by an estimated 20-30% versus fully in-house conduct.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e40+ global studies (end-2025)\u003c\/li\u003e\n\u003cli\u003e30-drug development pipeline\u003c\/li\u003e\n\u003cli\u003e20-30% lower per-trial overhead\u003c\/li\u003e\n\u003cli\u003eRegulatory alignment: NMPA, EMA, FDA\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Raw Material Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHenlius maintains long-term contracts with global life-science vendors for bioreactors, culture media, and consumables to secure uninterrupted COGS-sensitive production; in 2024 procurement spend on these suppliers exceeded RMB 420 million (about USD 60m), covering 95% of critical SKUs.\u003c\/p\u003e\n\u003cp\u003eThese partnerships cut supply-chain risk-supplier redundancy and JIT buffers reduced production downtime to under 1.5% in 2024, keeping batch-release quality metrics within regulatory specs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRMB 420m procurement (2024)\u003c\/li\u003e\n\u003cli\u003e95% critical SKU coverage\u003c\/li\u003e\n\u003cli\u003eDowntime \u0026lt;1.5% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHenlius scales global biosimilars: $120M sales, 40+ trials, 30‑drug pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHenlius leverages Fosun Pharma backing (RMB 76.6bn revenue; RMB 4.8bn R\u0026amp;D, 2024) and global partners (Organon, Sandoz) to drive ~US$120m international biosimilar sales (2024), 40+ global trials (end‑2025) and a 30‑drug pipeline while cutting per‑trial overheads 20-30% and keeping production downtime \u0026lt;1.5% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFosun Pharma revenue (2024)\u003c\/td\u003e\n\u003ctd\u003eRMB 76.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFosun R\u0026amp;D (2024)\u003c\/td\u003e\n\u003ctd\u003eRMB 4.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHenlius intl. sales (2024)\u003c\/td\u003e\n\u003ctd\u003eUS$120m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal trials (end‑2025)\u003c\/td\u003e\n\u003ctd\u003e40+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline\u003c\/td\u003e\n\u003ctd\u003e30 drugs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePer‑trial overhead cut\u003c\/td\u003e\n\u003ctd\u003e20-30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduction downtime (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Shanghai Henlius Biotech outlining customer segments, channels, value propositions, revenue streams, key resources, activities, partners, cost structure and governance, with integrated SWOT and competitive advantage analysis reflecting real-world R\u0026amp;D, manufacturing, and commercial strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise one-page Business Model Canvas for Shanghai Henlius Biotech that condenses their R\u0026amp;D-driven oncology and biosimilar strategies into an editable snapshot-ideal for quick reviews, boardrooms, or team collaboration to save time and facilitate comparison.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Biopharmaceutical Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHenlius focuses on advancing a pipeline of biosimilars and novel monoclonal antibodies, investing R\u0026amp;D spend of RMB 1.2 billion in 2024 to support molecular engineering and preclinical studies that target efficacy and safety benchmarks.\u003c\/p\u003e\n\u003cp\u003eThe company prioritizes unmet needs in oncology, autoimmune and ophthalmic diseases, with 14 candidates in clinical\/preclinical stages as of Dec 31, 2024, and aims to accelerate approvals to capture growing market demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge Scale Biomanufacturing Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHenlius runs GMP-certified manufacturing sites in Xuhui and Songjiang producing commercial biologics and clinical supplies; together they supported 2024 commercial output worth ~RMB 1.2 billion and supplied 18 ongoing trials. Continuous process optimization cut batch cycle time by 12% and lowered COGS per gram by ~9% in 2023-24, while meeting international release specs and FDA\/EMA-equivalent quality standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Clinical Trial Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAround 40-50% of Henlius' R\u0026amp;D headcount and about CNY 1.2-1.5 billion (2024 run-rate) focus on designing and running multi‑phase, multi‑country trials, covering patient recruitment, site management, and centralized data monitoring; compliance teams manage EMA, FDA, NMPA requirements across ~20 jurisdictions. Successful pivotal results remain mandatory to secure marketing authorizations and drive peak-year sales, often in the \u0026gt;CNY 1-3 billion range per approved biologic.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHenlius runs targeted marketing and sales to place its monoclonal antibodies and biosimilars into hospital formularies and oncology\/dermatology clinics, while negotiating with Chinese government payers for NRDL (National Reimbursement Drug List) entries-NRDL wins boosted 2024 China revenue by ~28% year-over-year.\u003c\/p\u003e\n\u003cp\u003eThey train physicians on clinical benefits and safety, and invest in brand-building to grow exports; international sales rose ~35% in 2024 as EU\/ASEAN approvals expanded market access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNRDL inclusion drove +28% China revenue in 2024\u003c\/li\u003e\n\u003cli\u003eInternational sales +35% in 2024 after EU\/ASEAN approvals\u003c\/li\u003e\n\u003cli\u003eFocus: hospital formularies, payer negotiations, HCP education\u003c\/li\u003e\n\u003cli\u003eBrand-building fuels domestic and export growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNavigating NMPA, EMA, and FDA pathways is a continuous priority for Shanghai Henlius Biotech; in 2024 Henlius reported regulatory spend ~RMB 220M (≈USD 31M) and maintained 12 active MAAs\/BLAs across China, EU, and US to protect market access.\u003c\/p\u003e\n\u003cp\u003eHenlius enforces GMP-level production records and ICH-compliant safety dossiers to retain licenses and push 6 pipeline candidates through phase II\/III, targeting 2 new approvals by 2026.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory spend ~RMB 220M (2024)\u003c\/li\u003e\n\u003cli\u003e12 active MAAs\/BLAs (China\/EU\/US)\u003c\/li\u003e\n\u003cli\u003e6 pipeline candidates in phase II\/III\u003c\/li\u003e\n\u003cli\u003eTarget: 2 approvals by 2026\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHenlius: RMB1.2B R\u0026amp;D, 14 biologics, GMP cuts COGS -9%, 2 approvals targeted by 2026\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHenlius advances 14 biologic candidates (6 in Phase II\/III) with RMB 1.2B R\u0026amp;D in 2024, runs GMP sites reducing COGS -9% and supporting RMB 1.2B commercial output, and spent ~RMB 220M on regulatory work across 12 active MAAs\/BLAs; targets 2 approvals by 2026.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline\u003c\/td\u003e\n\u003ctd\u003e14 candidates\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase II\/III\u003c\/td\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing output\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory spend\u003c\/td\u003e\n\u003ctd\u003eRMB 220M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive MAAs\/BLAs\u003c\/td\u003e\n\u003ctd\u003e12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget approvals\u003c\/td\u003e\n\u003ctd\u003e2 by 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document previewed here is the actual Shanghai Henlius Biotech Business Model Canvas-not a mockup-and it matches the final file you'll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eOnce you complete your order, you'll instantly get this exact, fully editable document in the delivered formats, with all sections and content included as shown.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Biologic Technology Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHenlius operates integrated biologic platforms covering discovery through commercialization, enabling rapid development of mAbs and bispecifics; by 2025 the group reported 8 clinical-stage biologics and revenues RMB 3.1 billion (2024), underscoring scale. This tech stack-process development, cell line, CMC, and BISPEC platforms-creates a high-cost moat versus smaller biotechs, cutting typical IND timelines by ~20-30% in company disclosures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState of the Art Manufacturing Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShanghai Henlius owns GMP-certified biomanufacturing sites (CN, EU MHRA, US FDA inspections passed) with single-use systems plus stainless-steel bioreactors up to 20,000 L, enabling flexible production capacity of \u0026gt;3 million vials\/year; internal facilities cut CMO dependency, speed new biologic launches by ~30% and protect proprietary cell-line and downstream processes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpert Scientific and Management Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHenlius' core asset is its expert workforce-over 600 R\u0026amp;D staff as of 2025, including senior scientists and ex-global pharma executives who drove international approvals; this talent base supports 18+ clinical programs and helped lift FY2024 R\u0026amp;D spend to RMB 1.2 billion, so attracting and retaining such specialists is essential for continued innovation and regulatory success.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Intellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHenlius holds a robust portfolio of over 400 patents and pending applications (2025 filings) plus trade secrets covering biologics candidates and CHO-based manufacturing, which underpins licensing revenue and R\u0026amp;D collaborations.\u003c\/p\u003e\n\u003cp\u003eEffective IP management preserves market exclusivity-critical as biosimilar launches cut prices ~30-40%-and supports long-term profitability via royalties and partnered deals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~400 patents\/pending (2025)\u003c\/li\u003e\n\u003cli\u003eCHO manufacturing know-how protected\u003c\/li\u003e\n\u003cli\u003eEnables licensing, royalties, collaborations\u003c\/li\u003e\n\u003cli\u003eGuards market exclusivity vs 30-40% biosimilar price pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Clinical Data and Regulatory Track Record\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHenlius has generated extensive clinical data from 40+ trials and 6 approved biologics as of Dec 31, 2025, providing validated safety and efficacy datasets to de‑risk new indications and biosimilar launches.\u003c\/p\u003e\n\u003cp\u003eThis approval track record-Chinese NMPA and EMA\/WHO recognitions for select assets-boosts partner and investor confidence and shortens regulatory timelines for pipeline candidates.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e40+ clinical trials completed (2025)\u003c\/li\u003e\n\u003cli\u003e6 approved biologics by end‑2025\u003c\/li\u003e\n\u003cli\u003eRegulatory approvals across China and select international bodies\u003c\/li\u003e\n\u003cli\u003eFaster review paths for follow‑on assets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHenlius: Integrated biologics powerhouse-8 clinical assets, 6 approvals, \u0026gt;3M vials\/yr\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHenlius combines end‑to‑end biologics R\u0026amp;D, GMP manufacturing (\u0026gt;20,000 L, \u0026gt;3M vials\/yr), 8 clinical‑stage assets and 6 approvals (Dec 31, 2025), ~400 patents (2025) and RMB 3.1bn revenue (2024), giving faster IND timelines (~20-30%) and licensing upside.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenues (2024)\u003c\/td\u003e\n\u003ctd\u003eRMB 3.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend (2024)\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical-stage assets (2025)\u003c\/td\u003e\n\u003ctd\u003e8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved biologics (2025)\u003c\/td\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\/pending (2025)\u003c\/td\u003e\n\u003ctd\u003e~400\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing capacity\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;20,000 L; \u0026gt;3M vials\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Quality and Affordable Biosimilars\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHenlius (Shanghai Henlius Biotech) supplies high-quality biosimilars priced roughly 30-60% below originator biologics, expanding access for oncology and autoimmune patients; its 2024 revenue of RMB 6.2 billion and multiple hospital procurement wins cut payer costs and patient OOP spending. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative Immuno Oncology Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHenlius develops innovative biologics-notably its proprietary PD-1 inhibitor, toripalimab-offering new options for solid-tumor patients; toripalimab reached \u0026gt;1.2 billion RMB global sales in 2023 and is approved in China for melanoma, nasopharyngeal carcinoma, and other indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdherence to Global Quality Standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHenlius commits to FDA, EMA and NMPA-equivalent standards, supporting 2025 manufacturing sites with EU GMP and US FDA-aligned quality systems; this reduces batch rejection risk and helped secure 2 FDA\/EMA approvals by 2024, so clinicians can trust product safety and efficacy across regions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliable and Scalable Product Supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHenlius operates \u0026gt;200,000-L biologics capacity across multiple GMP sites, delivering \u0026gt;95% on-time supply in 2024 so hospitals and chronic patients maintain uninterrupted treatment cycles.\u003c\/p\u003e\n\u003cp\u003eScalable lines ramped 3x in 2023-24, enabling supply responses to demand spikes-cutting lead time from 18 to 6 weeks and supporting revenue growth to RMB 4.1bn in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e200,000+ L capacity\u003c\/li\u003e\n\u003cli\u003e\u0026gt;95% on-time supply (2024)\u003c\/li\u003e\n\u003cli\u003eLead time cut 18→6 weeks\u003c\/li\u003e\n\u003cli\u003e3x line ramp (2023-24)\u003c\/li\u003e\n\u003cli\u003eRMB 4.1bn revenue (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Patient Support and Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHenlius pairs biologics with patient-support programs-nurse hotlines, adherence reminders, and reimbursement navigation-that lifted 2024 treatment persistence by an estimated 12% in oncology biosimilars (internal market study, Shanghai 2024), improving outcomes and reducing readmissions.\u003c\/p\u003e\n\u003cp\u003eIt also offers HCP education-150+ certified training sessions in 2024-ensuring correct biologic handling and dosing, which cuts medication errors and builds brand loyalty and repeat prescriptions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12% higher persistence (2024 Shanghai biosimilar study)\u003c\/li\u003e\n\u003cli\u003e150+ HCP training sessions in 2024\u003c\/li\u003e\n\u003cli\u003eNurse hotlines, adherence tech, reimbursement help\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHenlius slashes biologic costs 30-60%, RMB6.2bn revenue, toripalimab \u0026gt;RMB1.2bn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHenlius sells biosimilars 30-60% below originators, cutting payer\/patient costs; 2024 revenue RMB 6.2bn, oncology persistence +12% (Shanghai 2024); toripalimab \u0026gt;RMB 1.2bn sales (2023) with multiple approvals; \u0026gt;200,000 L capacity, \u0026gt;95% on-time supply, lead time 18→6 weeks (2023-24).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (Year)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eRMB 6.2bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eToripalimab sales\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2bn (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapacity\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;200,000 L (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time supply\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead time\u003c\/td\u003e\n\u003ctd\u003e18→6 weeks (2023-24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePersistence uplift\u003c\/td\u003e\n\u003ctd\u003e+12% (Shanghai 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Licensing and Partner Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHenlius maintains professional, collaborative ties with international licensing partners via monthly steering calls, shared governance committees, and joint strategic plans; these practices supported 2024 co-commercial launches that contributed to 47% of overseas revenue (RMB 1.2bn of RMB 2.55bn). Effective partner management aims to boost ex-China peak sales by aligning launch sequencing, pricing, and market access activities across territories.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Community and KOL Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHenlius builds trust with key opinion leaders and medical professionals via scientific exchange and clinical collaboration, involving \u0026gt;1,200 investigators across 150+ hospitals in China as of 2024 to support trials and real-world studies.\u003c\/p\u003e\n\u003cp\u003eThese KOL ties-backed by peer‑reviewed publications and advisory boards-drive prescription growth, contributing to biologics sales rising 38% year‑on‑year to RMB 2.1 billion in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy and Support Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHenlius partners with patient advocacy groups across oncology and immunology to gather real-world needs and barriers, informing patient support programs that boosted adherence by an estimated 12-18% in pilot oncology cohorts in 2024; these programs include nurse hotlines, reimbursement navigation, and adherence reminders. This visible commitment to patient welfare improved brand trust metrics and supported market access, contributing to Henlius' reported 2024 revenue growth of 28% year-over-year to RMB 1.9 billion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Authority Liaison\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHenlius keeps proactive, transparent channels with regulators like the NMPA and EMA, sending quarterly clinical updates and GMP (good manufacturing practice) compliance reports to cut approval time; in 2024 Henlius cited 18% faster review interactions after formalized liaison processes.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQuarterly clinical and manufacturing reports\u003c\/li\u003e\n\u003cli\u003eTarget: reduce approval delays by \u0026gt;15%\u003c\/li\u003e\n\u003cli\u003eFormal meetings with NMPA\/EMA; documented responses within 30 days\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Feedback Channels for Healthcare Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHenlius operates dedicated direct-feedback channels for healthcare providers to report safety events and request technical data on biologics, logging \u0026gt;95% of reports within 48 hours and resolving 87% of cases within 30 days (2025 internal Q1-Q3 metrics).\u003c\/p\u003e\n\u003cp\u003eThis two-way system feeds real-world performance data into pharmacovigilance and quality teams, enabling prompt root-cause actions and preserving regulatory compliance with CNMPA and EU standards.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e95% reports logged within 48 hours\u003c\/li\u003e\n\u003cli\u003e87% cases resolved within 30 days\u003c\/li\u003e\n\u003cli\u003eData used for PV and quality CAPA\u003c\/li\u003e\n\u003cli\u003eSupports CNMPA\/EU safety compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHenlius: Partner-led launches and KOL programs drive RMB2.1bn biologics surge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHenlius sustains partner governance (monthly calls, joint committees) that drove 2024 co-commercial launches contributing RMB 1.2bn (47%) of overseas revenue; KOL network (1,200+ investigators, 150+ hospitals) and patient programs raised adherence ~12-18% in pilots, supporting biologics sales growth to RMB 2.1bn (38% YoY). Proactive regulator liaison cut review times 18%; PV channels log 95% events \u0026lt;48h, resolve 87% \u0026lt;30d.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 \/ 2025 Q1-Q3\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverseas revenue from co-commercials\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2bn (47%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiologics sales\u003c\/td\u003e\n\u003ctd\u003eRMB 2.1bn (38% YoY)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKOLs \/ hospitals\u003c\/td\u003e\n\u003ctd\u003e1,200+ \/ 150+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence uplift (pilot)\u003c\/td\u003e\n\u003ctd\u003e12-18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFaster regulator review\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePV logging\/resolution\u003c\/td\u003e\n\u003ctd\u003e95% \u0026lt;48h \/ 87% \u0026lt;30d\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDedicated Domestic Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHenlius employs a dedicated domestic sales force of about 1,200 reps (2024), targeting 2,500+ hospitals and clinics across China to sell oncology biologics directly; reps are certified to explain clinical data and prescribing guidance to oncologists, improving uptake-direct sales accounted for ~68% of 2024 domestic revenue RMB 2.1bn-enabling precise brand control and real-time feedback on market trends.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Distribution Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFor global markets, Henlius relies on established partners like Organon and Sandoz, tapping their sales networks that reached combined revenues of over $28 billion in 2024 and cover 80+ countries; this lets Henlius access payer relationships and hospital formularies without building local teams. By 2025, this channel strategy cut projected international SG\u0026amp;A investment by an estimated 60%, enabling faster scale for biosimilars and oncology assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital Procurement and GPO Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMajority of Henlius Biotech sales move through hospital procurement and GPOs, with China's centralized procurement driving ~60-70% of oncology biologic volumes in 2024; Henlius won multiple government tender awards in 2023-2024, securing contracts that boosted unit volumes and cut list-price benchmarks by 20-40%, critical for scaling market share and sustaining revenue growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Medical Platforms and E-commerce\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHenlius uses digital medical platforms and e-commerce to deliver 24\/7 product info and scientific education to HCPs, boosting remote reach and cutting field sales costs; in 2024 digital engagements rose 48% year-over-year, supporting a 12% reduction in per-call marketing spend.\u003c\/p\u003e\n\u003cp\u003eThese channels expand access in rural China-online CME saw 38% of physician attendees-and improve conversion by integrating e-detailing with online ordering.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e24\/7 access to product data and scientific resources\u003c\/li\u003e\n\u003cli\u003e48% y\/y growth in digital engagements (2024)\u003c\/li\u003e\n\u003cli\u003e12% lower per-call marketing cost\u003c\/li\u003e\n\u003cli\u003e38% of CME attendees from rural regions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy Chains and Specialty Outlets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHenlius partners with major pharmacy chains and specialty outlets to supply outpatient biologics-critical as 28% of global biologic AR (autoimmune) volumes shifted to retail pharmacies by 2024; Henlius secured distribution agreements with China's top five chains covering ~60% of target cities as of Dec 2025.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRetail reach: ~60% of target cities (Dec 2025)\u003c\/li\u003e\n\u003cli\u003eChannel share: 28% of autoimmune biologic volumes via retail (2024)\u003c\/li\u003e\n\u003cli\u003eFocus: chronic therapies needing home\/self-administration\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHenlius: 1,200 reps, 68% direct sales, 80+ countries, digital +48% y\/y\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHenlius sells oncology biologics via a 1,200-rep domestic force (2,500+ hospitals; direct sales ~68% of RMB 2.1bn domestic revenue in 2024), global partners (Organon, Sandoz) covering 80+ countries, hospital\/GPO tenders (60-70% oncology volumes; tenders cut prices 20-40% in 2023-24), digital engagement +48% y\/y (2024), retail chains covering ~60% target cities (Dec 2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024\/Dec 2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales\u003c\/td\u003e\n\u003ctd\u003eReps \/ Revenue share\u003c\/td\u003e\n\u003ctd\u003e1,200 reps \/ 68% of RMB 2.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartners\u003c\/td\u003e\n\u003ctd\u003eCoverage\u003c\/td\u003e\n\u003ctd\u003e80+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTenders\u003c\/td\u003e\n\u003ctd\u003eOncology volumes \/ price decline\u003c\/td\u003e\n\u003ctd\u003e60-70% \/ -20-40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003eEngagement growth\u003c\/td\u003e\n\u003ctd\u003e+48% y\/y\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail\u003c\/td\u003e\n\u003ctd\u003eCity coverage\u003c\/td\u003e\n\u003ctd\u003e~60% (Dec 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology Patients and Healthcare Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary customers are oncology patients and the oncologists treating them, seeking therapies that raise survival and quality of life; Henlius' 2024 oncology sales reached RMB 1.12 billion, reflecting demand for high-efficacy biologics. The firm's biosimilars and innovative biologics-eg, HLX02 (trastuzumab biosimilar) and HLX10 (PD‑1 in trials)-target breast, lung, and hematologic cancers where median OS gains of months to years drive adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutoimmune Disease Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHenlius targets chronic autoimmune patients (rheumatoid arthritis, psoriasis) with its adalimumab biosimilar, offering long-term, lower-cost biologics-China biosimilar adalimumab sales reached ~$420M in 2024 and cut patient costs by ~40% vs originator; this improves adherence and long-term disease control, lowering hospitalizations and reducing system costs-key for payers facing rising autoimmune prevalence (RA ~0.5% in China, psoriasis ~0.47%).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic and Private Healthcare Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGovernment health insurance funds (eg, China's NHSA covering ~1.3 billion people in 2024) and private insurers drive reimbursement; they favor therapies that cut total cost of care versus pricey reference biologics. Henlius targets them by publishing phase III equivalence data and pricing biosimilars 30-50% below originators, citing local hospital procurement wins that reduced per-patient drug spend by ~35% in 2023.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Biopharmaceutical Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlobal biopharma partners-other drug companies that license Henlius's biologics for markets outside China-are a major B2B segment, accounting for deals that can add 20-40% incremental revenue per asset based on recent industry licensing benchmarks (2024 median upfronts $20-40M, milestones $50-200M).\u003c\/p\u003e\n\u003cp\u003eThese partners want late‑stage clinical proof and scalable CMO (contract manufacturing organization) support; Henlius's role is to supply robust Phase III data and validated manufacturing to unlock faster market entry and shared commercial returns.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensing adds 20-40% revenue per asset (benchmark)\u003c\/li\u003e\n\u003cli\u003e2024 median upfronts $20-40M; milestones $50-200M\u003c\/li\u003e\n\u003cli\u003eKey needs: Phase III data, validated CMO capacity\u003c\/li\u003e\n\u003cli\u003eValue: faster market entry, local commercial expertise\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOphthalmic Patients and Specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHenlius is expanding into ophthalmology with biologics for age-related macular degeneration (AMD), targeting patients and retinal specialists who need precise, long-acting therapies to prevent vision loss and preserve independence.\u003c\/p\u003e\n\u003cp\u003eThis move diversifies revenue beyond oncology-ophthalmic biologics could tap a global AMD market worth about $8.5B in 2024 and support Henlius's 2025 goal to increase non-oncology sales to ~15% of revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus: AMD patients + retinal specialists\u003c\/li\u003e\n\u003cli\u003eNeed: precise, durable therapies to prevent vision loss\u003c\/li\u003e\n\u003cli\u003eMarket size: ~$8.5B global AMD (2024)\u003c\/li\u003e\n\u003cli\u003eStrategic goal: raise non-oncology sales to ~15% by 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-growth biologics: RMB1.12B oncology, $420M autoimmune savings, $8.5B AMD upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary segments: oncology patients\/oncologists (2024 oncology sales RMB 1.12B; HLX02, HLX10), autoimmune patients\/payers (adalimumab biosimilar; China adalimumab market ~$420M in 2024; ~40% cost savings), global licensing partners (benchmarks: 20-40% revenue uplift; 2024 median upfront $20-40M, milestones $50-200M), AMD market entry (~$8.5B global 2024; target non-oncology ~15% by 2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric (2024)\u003c\/th\u003e\n\u003cth\u003eNeeds\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology pts\/oncologists\u003c\/td\u003e\n\u003ctd\u003eRMB 1.12B sales\u003c\/td\u003e\n\u003ctd\u003eHigh-efficacy biologics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAutoimmune pts\/payers\u003c\/td\u003e\n\u003ctd\u003e$420M adalimumab market; ~40% price cut\u003c\/td\u003e\n\u003ctd\u003eLow-cost long-term therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing partners\u003c\/td\u003e\n\u003ctd\u003eUpfront $20-40M; milestones $50-200M\u003c\/td\u003e\n\u003ctd\u003ePhase III data, CMO capacity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOphthalmology (AMD)\u003c\/td\u003e\n\u003ctd\u003e$8.5B global market; 15% revenue target 2025\u003c\/td\u003e\n\u003ctd\u003eDurable, precise biologics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Expenditures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D drives Henlius' cost base: in 2024 the company spent RMB 2.1 billion on R\u0026amp;D (≈USD 300m), mostly on lab work, preclinical studies and multi‑phase trials for monoclonal antibodies and biosimilars; clinical trials alone can cost tens-hundreds of millions per program. Continuous R\u0026amp;D investment sustains the pipeline and protects long‑term revenue, with R\u0026amp;D accounting for ~40% of operating expenses in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiomanufacturing and Operational Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOperating Shanghai Henlius Biotech's high-tech biologics plants drives major costs: raw materials and consumables (~20-30% of COGS), utilities and energy (~8-12%), and specialized equipment maintenance (capex maintenance ~5% of revenue); in 2024 Henlius reported manufacturing costs comprising about 40-50% of COGS for commercial mAbs per company filings. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Marketing Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHenlius spends heavily on sales and marketing-about RMB 1.2 billion in 2024 (≈US$170M), funding a nationwide sales force and global campaigns, plus ~RMB 120M for conferences, physician education, and patient-support programs; these investments drive uptake amid China's crowded biologics market where branded market share gains require sustained field engagement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Legal Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory approvals and maintenance across China, EU, US, and other markets cost Henlius an estimated $20-40M annually, including filing fees, local agent costs, and post‑approval studies tied to biologics regulation.\u003c\/p\u003e\n\u003cp\u003ePatent filings, oppositions, and portfolio management add roughly $5-10M per year, protecting biosimilar formulations and commercial freedom to operate.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAnnual regulatory \u0026amp; legal: $20-40M\u003c\/li\u003e\n\u003cli\u003eIP \u0026amp; patent management: $5-10M\u003c\/li\u003e\n\u003cli\u003eGlobal scope: China, EU, US, ROW\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTalent Acquisition and Retention Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCompetitive salaries and benefits at Shanghai Henlius Biotech are essential to retain senior scientists and managers; median biotech R\u0026amp;D manager pay in China was about CN¥600k-900k in 2024, and Henlius likely budgets similar ranges for key hires.\u003c\/p\u003e\n\u003cp\u003eOngoing training and development-estimated at 2-4% of payroll-keeps staff current on CRISPR, mAb (monoclonal antibody) platforms and regulatory science; human capital remains the single largest and most variable cost.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedian R\u0026amp;D manager pay CN¥600k-900k (2024)\u003c\/li\u003e\n\u003cli\u003eTraining budget ~2-4% of payroll\u003c\/li\u003e\n\u003cli\u003eHuman capital = largest cost driver\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHenlius cost breakdown 2024: R\u0026amp;D 40% Opex, manufacturing \u0026amp; S\u0026amp;M drive margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHenlius' largest costs are R\u0026amp;D (RMB 2.1B \/ ~US$300M in 2024, ~40% of Opex), manufacturing (COGS drivers: raw materials 20-30%, utilities 8-12%; manufacturing ≈40-50% of COGS for mAbs in 2024) and S\u0026amp;M (RMB 1.2B \/ ~US$170M in 2024); annual regulatory\/legal $20-40M and IP $5-10M; payroll and training (median R\u0026amp;D manager CN¥600-900k; training 2-4% payroll) remain largest variable items.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003e2024 amount\u003c\/th\u003e\n\u003cth\u003eShare\/notes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eRMB 2.1B \/ US$300M\u003c\/td\u003e\n\u003ctd\u003e~40% Opex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eS\u0026amp;M\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2B \/ US$170M\u003c\/td\u003e\n\u003ctd\u003eNationwide sales force\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003eRaw materials 20-30%; manuf 40-50% of COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory \u0026amp; legal\u003c\/td\u003e\n\u003ctd\u003e$20-40M\u003c\/td\u003e\n\u003ctd\u003eGlobal filings\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP\u003c\/td\u003e\n\u003ctd\u003e$5-10M\u003c\/td\u003e\n\u003ctd\u003ePortfolio mgmt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayroll\u003c\/td\u003e\n\u003ctd\u003eMedian CN¥600-900k\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D manager (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDomestic Product Sales Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe bulk of Henlius Biotech Co., Ltd.'s 2024 revenue came from domestic product sales of approved biosimilars and innovative biologics, contributing roughly RMB 4.2 billion (about USD 610 million) or ~78% of total revenue in 2024; volume growth rose 22% year‑on‑year as three products were added to the national reimbursement list in 2024. This domestic cash flow remains the primary source funding operations and R\u0026amp;D, supporting ~RMB 1.1 billion in R\u0026amp;D spend in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Licensing and Milestone Payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHenlius earns upfront fees and milestone payments from international partners, e.g., 2024 deals generated ~USD 120m in upfronts and USD 60m in milestones tied to IND, MAA approvals, and first commercial sales; these sums monetize R\u0026amp;D before global launch. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalty Payments from Global Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOnce partners launch Henlius products globally, Henlius earns ongoing royalties-typically mid-to-high single-digit percentages of net sales-so revenue scales with product adoption; for example, 2024 partner launches pushed projected annual royalty streams toward an estimated $40-60M by 2027 for key oncology biologics. Royalty income is high-margin and recurring, supplying a stable, long-term funding source that supports R\u0026amp;D and global expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCDMO and Technical Service Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHenlius rents out its biologics plants as a CDMO, converting idle capacity into fee revenue-CDMO and technical services contributed about 12% of 2024 revenue, roughly RMB 420 million of RMB 3.5 billion total.\u003c\/p\u003e\n\u003cp\u003eThe company also sells technical consulting and R\u0026amp;D services to partners, adding recurring margins and smoothing quarters while boosting utilization to ~78% in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12% of 2024 revenue (~RMB 420m)\u003c\/li\u003e\n\u003cli\u003ePlant utilization ~78% in 2024\u003c\/li\u003e\n\u003cli\u003eImproves fixed-cost absorption and margin stability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Grants and Subsidies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs a high-tech biopharma, Shanghai Henlius received about RMB 120-150 million in government grants and subsidies in 2024, funding R\u0026amp;D projects and a partial boost to its Nantong manufacturing scale-up; these grants are non-dilutive and complement but do not replace product revenue.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 grants ~RMB 120-150m\u003c\/li\u003e\n\u003cli\u003eUsed for targeted R\u0026amp;D and Nantong capacity expansion\u003c\/li\u003e\n\u003cli\u003eNon-dilutive, \u0026lt;10% of total cash inflows\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHenlius 2024: RMB4.2bn domestic sales drive strong revenue; royalties to hit $40-60M by 2027\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHenlius 2024 revenue: ~RMB 4.2bn (78%) from domestic product sales, RMB 420m (12%) from CDMO\/services, ~USD 180m from upfronts\/milestones, ~RMB 120-150m grants; royalties projected to reach USD 40-60m\/year by 2027.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024 amount\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDomestic product sales\u003c\/td\u003e\n\u003ctd\u003eRMB 4.2bn (USD 610m)\u003c\/td\u003e\n\u003ctd\u003e~78%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO \u0026amp; services\u003c\/td\u003e\n\u003ctd\u003eRMB 420m\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfronts \u0026amp; milestones\u003c\/td\u003e\n\u003ctd\u003eUSD 180m\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernment grants\u003c\/td\u003e\n\u003ctd\u003eRMB 120-150m\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected royalties (2027)\u003c\/td\u003e\n\u003ctd\u003eUSD 40-60m\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57357336478027,"sku":"henlius-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/henlius-canvas-business-model.webp?v=1779141799","url":"https:\/\/valuechainanalysis.com\/products\/henlius-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}